Pierrel has achieved another objective of the 2013-2015 industrial plan: the penetration of its flagship product Orabloc – the dental anesthetic produced at the Capua plant, near Naples – in the North American market marks a +33,3% total sales to the end customer, i.e. to US and Canadian dentists. In the wake of the results, the exploit on the stock market arrived this morning, where Pierrel gained 6% in mid-morning, at 0,5655 euros per share.
The sales figure emerges from the comparison of the period between October 2012 and September 2013 and the analogous period between 2011 and 2012 and proves the strong commercial commitment that Pierrel has deployed in the area in question. A commitment that has made use of the collaboration of the largest global distributors of dental care (Patterson Dental, Henry Schein, Benco Dental, Sinclair and DC Dental), but above all of a vast communication campaign aimed at North American dentists through a dedicated call center.
The campaign paid off quickly. Launched at the end of the summer, it delivers to Pierrel the consolidation of sales in September 2013, compared to those already obtained in August 2013, and a firm forecast of a further improvement in sales performance by the end of 2013.
